XNAS
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | Q1 2026 | — | -6.28 | — | $8.6M | — | -0.83% | +13.31% | — |
| 2026-04-10 | Q4 2025 | -0.47 | -4.60 | -878.72% | $4.8M | ❌ Miss | +0.74% | +1.47% | +1.47% |
| 2025-11-14 |
| Q3 2025 |
| 0.07 |
| -22.17 |
| -31771.43% |
| $10.6M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | -0.91 | -7.42 | -715.38% | $9.9M | ❌ Miss | +4.33% | -16.33% | +25.14% |
| 2025-03-31 | Q4 2024 | — | -0.05 | — | $14.9M | — | -4.43% | +0.00% | -45.50% |
| 2025-01-17 | Q3 2024 | -0.10 | -0.03 | +70.00% | $14.4M | ✅ Beat | -5.79% | -1.92% | -21.27% |
| 2024-08-13 | Q2 2024 | -0.20 | -0.31 | -55.00% | $16.4M | ❌ Miss | -4.58% | -3.82% | -19.08% |
| 2024-05-13 | Q1 2024 | -0.10 | -0.24 | -140.00% | $10.9M | ❌ Miss | -0.61% | +50.33% | +78.90% |
Showing last 8 quarters.